جزییات کتاب
Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion. A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combined therapies and additional considerations that arise from multi-agent programs are highlighted.Content: Chapter 1 Similarities and differences in the pathophysiology of asthma and COPD (pages 1–15): J. Christian VirchowChapter 2 Glucocorticoids: Pharmacology and Mechanisms (pages 16–37): Peter J. BarnesChapter 3 Inhaled Corticosteroids: Clinical Effects in Asthma and COPD (pages 38–52): Paul M. O'Byrne and Desmond M. MurphyChapter 4 LABAs: Pharmacology, Mechanisms and Interaction with Anti‐Inflammatory Treatments (pages 53–80): Gary P. AndersonChapter 5 Long‐ And Ultra‐Long‐Acting β22‐Agonists (pages 81–101): Mario Cazzola and Maria Gabriella MateraChapter 6 The Safety of Long‐Acting Beta‐Agonists and the Development of Combination Therapies for Asthma and COPD (pages 102–134): Victor E. Ortega and Eugene R. BleeckerChapter 7 Inhaled Combination Therapy with Glucocorticoids and Long‐Acting β2‐Agonists in Asthma and COPD, Current and Future Perspectives (pages 135–153): Jan LötvallChapter 8 Novel Anti‐Inflammatory Treatments for Asthma and COPD (pages 154–202): Paul A. Kirkham, Gaetano Caramori, K. Fan Chung and Ian M. AdcockChapter 9 Novel Biologicals Alone and in Combination in Asthma and Allergy (pages 203–231): Sharmilee M. Nyenhuis and William W. BusseChapter 10 Anti‐Infective Treatments in Asthma and COPD (pages 232–267): Jonathan D. R. Macintyre and Sebastian L. JohnstonChapter 11 Long‐Acting Muscarinic Antagonists in Asthma and COPD (pages 268–295): M. Diane Lougheed, Josuel Ora and Denis E. O'DonnellChapter 12 Phosphodiesterase Inhibitors in Obstructive Lung Disease (pages 296–310): Jan Lötvall and Bo LundbäckChapter 13 Biological Therapies in Development for COPD (pages 311–332): J. Morjaria and R. PolosaChapter 14 ‘Triple Therapy’ in the Management of COPD: Inhaled Steroid, Long‐Acting Anticholinergic and Long‐Acting β2‐Agonist (pages 333–342): Ronald Dahl